Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 2, 2005, Pages 250-253

  Griffith, David E ^a   Brown Elliott, Barbara A ^b   Shepherd, Sara ^b   McLarty, Jerry ^b   Griffith, Lee ^b   Wallace Jr , Richard J ^b  

^a Health Science Center   (United States)

^b NONE

Author keywords

Ethambutol; Mycobacterium avium complex

Indexed keywords

ETHAMBUTOL;

ADULT; AGED; ARTICLE; BRONCHIECTASIS; COLOR VISION; CONSULTATION; CONTROLLED STUDY; DRUG WITHDRAWAL; EYE TOXICITY; FEMALE; HUMAN; LUNG INFECTION; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; SYMPTOMATOLOGY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; ETHAMBUTOL; EYE DISEASES; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION;

EID: 22144468078     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200407-863OC     Document Type: Article

References (24)

1. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996;153(6):1766-1772.
2. Griffith DE, Brown BA, Girard WM, Griffith BE, Couch LA, Wallace RJ Jr. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 2001;32(11):1547-1553.
3. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, Suzuki K, Murayama T, Amitani R, Kuze F. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999;160(3):866-872.
4. Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley SL, Fong IW, Gill MJ, Rachlis AR, Lalonde RG, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med 1996;335: 377-383.
5. Gordin FM, Sullam PM, Shafran SD, Cohn DL, Wynne B, Paxton L, Perry K, Horsburgh CR Jr. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis 1999;28(5):1080-1085.
6. Benson CA, Williams PL, Currier JS, Holland F, Mahon LF, MacGregor RR, Inderlied CB, Flexner C, Neidig J, Chaisson R, et al., for the AIDS Clinical Trials Group 223 Protocol Team. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 2003;37:1234-1243.
7. Schild HS, Fox BC. Rapid-onset reversible ocular toxicity from ethambutol therapy. Am J Med 1991;90(3):404-406.
8. Kahana LM. Toxic ocular effects of ethambutol. Can Med Assoc J 1987; 137:213-216.
9. Alvarez KL, Krop LC. Ethambutol-induced ocular toxicity revisited. Ann Pharmacother 1993;21(1):102-103.
10. Leibold JE. The ocular toxicity of ethambutol and its relation to dose. Ann NY Acad Sci 1966;135:904-909.
11. Russo PA, Chaglasian MA. Toxic neuropathy associated with ethambtuol: implications for current therapy. J Am Optom Assoc 1994;65:332-338.
12. Kumar A, Sandramouli S, Verma L, Tewari HK, Khosla PK. Ocular ethambutol toxicity: is it reversible? J Clin Neuroopthalmol 1993;13: 15-17.
13. Chatterjee VK, Buchanan DR, Friedmann AI, Green M. Ocular toxicity following ethambutol in standard dosage. Br J Dis Chest 1986;80(3): 288-291.
14. Addington WW. The side effects and interactions of antituberculosis drugs. Chest 1979;76(Suppl):782-784.
15. Sbarbaro JA, Hudson LD. High dose ethambutol; an oral alternate for intermittent chemotherapy. Am Rev Respir Dis 1974;110(1):91-94.
16. Albert RK, Sbarbaro JA, Hudson LD, Iseman M. High-dose ethambutol: its role in intermittent chemotherapy: a six-year study. Am Rev Respir Dis 1976;114(4):699-704.
17. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
18. Bass JB Jr, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, Snider DE Jr, Thornton G. Treatment of tuberculosis and tuberculosis infection in adults and children: American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994;149(5):1359-1374.
19. Pierce JR, Denison AV. Letter to the editor. JAMA 1994;271:104-105.
20. Griffith DE, Elliott-Brown B, Shephard S, McLarty J, Griffith L, Wallace RJ Jr. Ethambutol ocular toxicity in multidrug treatment regimens for Mycobacterium avium complex lung disease [abstract]. Am J Respir Crit Care Med 2001;163:A763.
21. Wallace RJ Jr, Glassroth J, Griffith DE, Olivier KN, Cook JL, Gordin F. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997;156(2):S1-S25.
22. Humes HD, editor. Kelley's textbook of internal medicine. 4th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2000.
23. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-1477.
24. Citron KM, Thomas GO. Ocular toxicity from ethambutol. Thorax 1986;41(10):737-739.